MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma
Oncogene2012Vol. 32(3), pp. 277–285
Citations Over TimeTop 10% of 2012 papers
Kerstin Boll, Kristin Reiche, Katharina Kasack, Nora Mörbt, A. Kretzschmar, Janina M. Tomm, Gerald W. Verhaegh, Jack A. Schalken, Martin von Bergen�, Friedemann Horn, Jörg Hackermüller
Related Papers
- Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.(2001)
- → Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system(1999)420 cited
- → p-Carborane-based androgen antagonists active in LNCaP cells with a mutated androgen receptor(2011)27 cited
- → Abstract 3930: Ligand-independent activity of the mutant LNCaP androgen receptor drives cell proliferation in hormone-independent LNCaP tumor cells(2012)1 cited
- Cell growth promoting of the androgen receptor mutation(2006)